Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

@article{Chen2014PharmacokineticsOV,
  title={Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.},
  author={Xia Chen and Teddy Kosoglou and Paul Statkevich and Bharath Rathna Kumar and Jing Li and Marissa F Dockendorf and Guoqin Q Wang and Robert S. Lowe and Ji Jiang and Hongzhong Liu and Zaiqi Wang and David L. Cutler and Pei Hu},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2014},
  volume={52 10},
  pages={889-99}
}
AIM Vorapaxar is a proteaseactivated receptor (PAR)-1 antagonist being developed for the prevention and treatment of thrombotic vascular events. To evaluate race/ethnic differences between Caucasians and Chinese in the pharmacokinetics of vorapaxar and its active metabolite SCH 2046273 (M20) or in the metabolite/parent ratio, we conducted a cross-study comparison on pharmacokinetic data of vorapaxar and M20 obtained from two similarly designed studies: one in healthy Chinese subjects and the… CONTINUE READING

From This Paper

Topics from this paper.